Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
521-540 of 1,743 trials

Aggressive Large B-Cell Lymphoma: Golcadomide After CAR T-Cell Therapy

We are studying whether golcadomide can improve outcomes for patients with aggressive large B-cell lymphoma after receiving CAR T-cell therapy. The trial will look at response rates and safety in those at high risk of relapse.

Aggressive Large B-Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Mantle-Cell Lymphoma: Glofitamab with Venetoclax and Zanubrutinib

We are studying a new treatment combination for patients with untreated or relapsed high-risk mantle-cell lymphoma. The trial aims to see if this combination works better than Venetoclax alone.

Mantle-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

ALK Positive Non-Small Cell Lung Cancer: Chemotherapy Plus Lorlatinib

We are studying a combination of chemotherapy and Lorlatinib for patients with ALK positive NSCLC who have had disease progression outside the brain. The goal is to see if this treatment improves outcomes compared to past therapies.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Glioblastoma: [177Lu]Lu-DOTA-TATE Treatment Study

We are exploring a new drug for patients with newly diagnosed glioblastoma alongside standard care, and for those with recurrent glioblastoma as a single treatment. The goal is to find the best dose for effective treatment.

Glioblastoma>2 yearsSafety phase (I)NeurologyOncology

Familial Mediterranean Fever: On-Demand Anakinra Treatment

We are studying whether on-demand Anakinra can help patients with colchicine-resistant FMF manage painful attacks without daily therapy. This trial compares its effectiveness to standard pain management options.

Familial Mediterranean Fever>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInfectious DiseasesInternal MedicineRheumatology

Penile Cancer: Carboplatin, Paclitaxel, and Pembrolizumab Study

We are studying a combination of chemotherapy and immunotherapy for patients with locoregionally advanced penile cancer. The goal is to see if this treatment can effectively shrink tumors before surgery and to assess its safety.

Locoregionally Advanced Penile Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Duchenne Muscular Dystrophy: BMN 351 Treatment Study

We are testing a new treatment called BMN 351 to see if it is safe and well-tolerated in people with Duchenne Muscular Dystrophy. The study will also look at how the drug is processed in the body.

Duchenne Muscular Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Advanced Gastric Cancer: EXL01 with Nivolumab and FOLFOX

We are studying a new treatment combination for patients with advanced gastric cancer to see if it improves response rates and safety. This trial focuses on those with a specific biomarker to better understand treatment effectiveness.

Metastatic Gastric Adenocarcinoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Non-Small Cell Lung Cancer: STX-721/PFL-721 Treatment

We are studying a new treatment for people with non-small cell lung cancer who have specific mutations. The goal is to see if it can improve their condition compared to standard therapies.

Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Lung Cancer: Selpercatinib Study

We are testing a new treatment called selpercatinib for patients with RET fusion-positive non-small cell lung cancer. The goal is to see if it improves outcomes compared to a placebo.

RET Fusion-Positive Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Adrenomyeloneuropathy: Dimethyl Fumarate Study

We are investigating whether dimethyl fumarate can improve symptoms in patients with adrenomyeloneuropathy compared to a placebo. The trial also looks at the safety of this medication.

Adrenomyeloneuropathy>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Pain Relief for Kids: Fentanyl vs. Ketamine vs. Morphine

We are studying whether intranasal fentanyl or ketamine is more effective than oral morphine for reducing pain in children with limb injuries. This trial involves children aged 2 to 17 in emergency departments.

Limb InjuriesUrgency>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

LSTA1 for Newly Diagnosed Glioblastoma Multiforme

We are studying whether adding LSTA1 to standard treatment (temozolomide) improves survival for patients with newly diagnosed GBM compared to a placebo. The trial also looks at quality of life and other important health measures.

Glioblastoma Multiforme>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementOncology

Prostate Cancer: Intermittent vs. Continuous Hormone Therapy

We are studying whether intermittent hormone therapy can maintain effectiveness and improve daily life for men with advanced prostate cancer. This trial compares it to continuous hormone therapy to see which is better for patients.

Hormone-sensitive Metastatic Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

CP-506 for Solid Tumors: A New Treatment Study

We are testing a new drug, CP-506, in patients with specific solid tumors to see how safe it is and how well it works. This study may help those with tumors that have certain genetic features or who are not responding well to current treatments.

Solid Tumors with DNA Repair Deficiencies>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Recurrent Gynecological Cancers: IMGN151 Study

We are testing a new drug, IMGN151, in women with recurrent gynecological cancers to assess its safety and determine the best dose. This study aims to understand how well the drug works and its effects on patients.

Recurrent Gynecological Cancers>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Mycobacterium Xenopi Infection: ARIKAYCE Inhalation Treatment

We are studying whether adding ARIKAYCE to standard treatment helps people with Mycobacterium xenopi lung infections clear the infection more effectively. The trial will measure how quickly and effectively the treatment works compared to standard care alone.

Mycobacterium xenopi Pulmonary Infection>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Chronic Kidney Disease: Teriparatide for Bone Health

We are studying whether teriparatide can improve bone metabolism in patients with chronic kidney disease and adynamic bone disorder. This trial compares the effects of treatment to no treatment at all.

Adynamic Bone Disorder>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNephrologyOrthopedics and Traumatology

Solid Tumors: IMA401 TCER® Treatment

We are testing a new bispecific T-cell receptor treatment for patients with solid tumors. The study looks at its effects alone and with a checkpoint inhibitor to see how well it works.

Solid Tumors>2 yearsSafety phase (I)Oncology

Staphylococcus Aureus Bacteraemia: Bensylpenicillin vs. Cloxacillin

We are comparing two antibiotics to see which one works better for patients with a specific bacterial infection. The study looks at treatment outcomes, relapse rates, and side effects.

Staphylococcus aureus Bacteraemia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine